Current version snapshot
Current · version 3: Ipamorelin↗
Related names recorded in this version: Ipamorelin acetate↗
A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin. 316
What this version reported
FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗
Reader guide in this version
Key takeaway
Ipamorelin is a lab-made five-amino-acid peptide that mimics ghrelin, a hormone that stimulates growth hormone release. It was first synthesized by Novo Nordisk researchers in the mid-1990s.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that neither ipamorelin nor ipamorelin acetate is a component of an FDA-approved drug.3 Its main human study, a small randomized trial after bowel surgery, did not show a statistically significant benefit, and FDA concluded the evidence for growth hormone deficiency or recovery after surgery is limited.3 FDA staff recommended against adding ipamorelin to the list of substances pharmacies may use in compounding, and ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,6
At a glance
- What it is
- A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.3
- FDA status
- Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.1,3
- Human evidence
- One small randomized, placebo-controlled trial after bowel surgery that found no statistically significant benefit, and a placebo-controlled pharmacology study in 48 healthy men.3
- Sport status
- FDA’s 2024 briefing notes that ipamorelin is on the World Anti-Doping Agency’s prohibited list under section S2.4.3
- Evidence strength
- Smaller controlled human trials
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide, a chain of five amino acids that includes unnatural amino acids. FDA describes it as a ghrelin mimetic, meaning it imitates ghrelin, a hormone that stimulates growth hormone release.3
FDA’s briefing states that Novo Nordisk researchers first synthesized it in the mid-1990s and that it was first described in the literature in 1998. It exists as a free base and as an acetate salt, which FDA treats as different substances.3
FDA found it marketed by wellness clinics and medical spas for uses such as weight loss, anti-aging, sleep and bodybuilding, sometimes combined with other peptides such as sermorelin. Outsourcing facilities reported compounding it from 2017 to 2020.3
How is ipamorelin thought to work?
FDA’s briefing describes ipamorelin as acting mainly through ghrelin receptors in the brain and on pituitary cells to stimulate growth hormone release.3
FDA notes that peptides with unnatural amino acids are harder to characterize, and that impurities or clumping of peptide chains could make immune reactions more likely.3
What do human studies show?
FDA found one clinical study of ipamorelin’s effectiveness: a Phase 2, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults having bowel surgery, published in 2014, in which 114 received ipamorelin or placebo.3
The median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference the study reported as not statistically significant. Secondary measures of bowel recovery and hospital stay also showed no differences.3
FDA notes that adverse events in that trial included low potassium, insomnia, high blood sugar, nausea, vomiting, abdominal swelling and two deaths, and that it is unclear whether the deaths were related to ipamorelin. FDA cites a later report that development for this use was discontinued.3
The study cited to FDA for growth hormone deficiency was a randomized, placebo-controlled pharmacology study in 48 healthy men that reported no effectiveness data. FDA found no other publications evaluating ipamorelin for growth hormone deficiency.3
What the evidence base contains
- Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.3
- Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is ipamorelin FDA-approved?
No. FDA’s evaluation, dated August 19, 2024, states that neither ipamorelin (free base) nor ipamorelin acetate is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.3
FDA staff evaluated both forms for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency and recovery of bowel function after surgery. They concluded that the balance of criteria weighs against adding either form, citing poor characterization data, limited evidence of effectiveness and safety concerns.3
A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss ipamorelin-related substances at its October 29, 2024 meeting. FDA’s briefing states that FDA will not issue a final determination until the committee’s input has been considered and all reviews are finalized.3,4
FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.5,6
FDA’s briefing also notes that Australia’s medicines scheduling committee added ipamorelin to its Poisons Standard as a performance and image enhancing drug. None of the sources reviewed here reports an approval of ipamorelin in any country.3
Timeline
- Ipamorelin is first described in the scientific literature, according to FDA’s briefing.3
- Ipamorelin acetate is placed in category 2 under FDA’s 503B interim policy, according to FDA’s compounding safety-risk page.1
- FDA staff date their evaluation recommending against adding ipamorelin to the 503A bulks list.3
- A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.4
- FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.3,4
- FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.1
What is still unknown?
Whether ipamorelin has any clinical benefit: FDA found the evidence for growth hormone deficiency and recovery after surgery limited.3
Its safety in the compounded form that was nominated, for which FDA says there are no safety data.3
What is in products sold under the name: FDA notes that the free base and acetate forms are different substances and that the nominations did not make clear which one was proposed.3
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 3FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 4Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026
- 5Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026